New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:

• GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia 
• BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)

Presenters:

Christopher R. Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center 
Houston, Texas

Kami Maddocks, MD
Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.